contrave glp 1 GLP-1 receptor agonists (semaglutide or tirzepatide) and (naltrexone/bupropion) show promise in addressing food addiction by targeting appetite and reward pathways in the brain. GLP-1 agonists regulate hunger by slowing gastric emptying Contrave vs. Ozempic: A head-to-head

Witness the transformation within weeks

Private insurers are dropping coverage, or capping costs by erecting complex hurdles before theyll consider covering a GLP-1 drug

In a statement, Lilly USA President Ilya Yuffa said far too many people who need obesity medication "still face cost and coverage barriers." The drugmaker's price cuts "underscores Lillys commitment to improving access across the obesity care landscape," Yuffa said

Competing oral GLP-1 products Multiple pharmaceutical companies are developing oral GLP-1 agonists that may eventually compete with semaglutide

This is an important insight because it sets the stage, at least in principle, for MS potentially being triggered by subtle injury to CNS myelin rather than by a primary autoimmune assault

Swipe through the carousel to see exactly what these changes mean for your clinical workflows